Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NUVB vs AQST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AQST Captures Overall Composite Edge (62.9 BUY vs 61.0 BUY), While NUVB Leads 3–2 on Growth & Valuation Pillars
AQST Overall Winner
6-Pillar Tally: NUVB 3 – 2 AQST (1 Tie)
Matrix Metrics: NUVB 5 – 3 AQST
As of Nov 20, 2026, Aquestive Therapeutics, Inc. (AQST) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (62.9/100 BUY vs. 61.0/100 BUY) after splitting the core matrix 3–5 (led by Balance Sheet & Cash Flow, Options & Positioning), while NUVB wins 3–2 across the 6-pillar growth and valuation breakdown. NUVB trades at $3.80 (N/M Forward P/E, -61.2% operating margin) versus AQST at $3.46 (N/M Forward P/E, -114.1% operating margin).
- Growth vs. Quality Trade-Off: AQST earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. NUVB 61.0/100 BUY) and 0.89β · 56% Vol risk profile, whereas NUVB leads top-line expansion (+242.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About NUVB vs AQST
NUVB
Nuvation Bio Inc.
$3.80
-0.26% 1D
Market Cap
$1.3B
TTM Revenue
$202M
Forward P/E
N/M
Beta / 30D Vol
1.52β · 55% Vol
Unified Composite Score
61.0
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
AQST
Head-to-Head Winner
Aquestive Therapeutics, Inc. Common Stock
$3.46
-6.61% 1D
Market Cap
$465.7M
TTM Revenue
$49M
Forward P/E
N/M
Beta / 30D Vol
0.89β · 56% Vol
Unified Composite Score
62.9
BUY
Tech 54.0
Fund 68.0
Flow 68.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (NUVB 3 – 2 AQST)
1. Valuation Multiples
NUVB
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
7.4x
8.9x
2. Growth & Scale
NUVB
Revenue Growth (YoY)
+242.6%
-41.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$202M
$49M
Market Cap
$1.3B
$465.7M
3. Profitability & Quality
NUVB
Gross Margin
85.8%
65.3%
Operating Margin
-61.2%
-114.1%
Net Profit Margin
-67.4%
-162.3%
Return on Equity (ROE)
-49.1%
0.0%
4. Balance Sheet & Cash Flow
AQST
Cash Generation (TTM)
-$108M
-$41M
Cash Flow Margin
-53.6%
-83.3%
Net Cash / Leverage
$146M Net Debt (1.32x D/E)
$32M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
AQST
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
65.2% (26th %ile)
87.9% (64th %ile)
Put/Call OI Skew
0.24x (Call-Skewed)
0.98x (Balanced)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Drug Manufacturers - Specialty & Generic Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: NUVB (5) vs AQST (3)| Institutional Metric | NUVB | AQST | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.3B | $465.7M | NUVB | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +242.6% | -41.0% | NUVB | |
| Operating Margin (TTM) | -61.2% | -114.1% | NUVB | |
| Net Profit Margin | -67.4% | -162.3% | NUVB | |
| Return on Equity (ROE) | -49.1% | 0.0% | AQST | |
| 52-Week Range Position | 2% ($4–$10) | 14% ($3–$7) | AQST | |
| Beta / 30D Volatility | 1.52β · 55% Vol | 0.89β · 56% Vol | NUVB | |
| Unified Institutional Score | 61.0 / 100 (BUY) | 62.9 / 100 (BUY) | AQST | |
| Trailing 12M Revenue (USD) | $202M | $49M | Scale | |
| Gross Profit Margin (TTM) | 85.8% | 65.3% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 7.4x EV/Rev | N/M PEG · 8.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$108M ($146M Net Debt (1.32x D/E)) | -$41M ($32M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
AQST +2.93 pp
3M Horizon
AQST +15.87 pp
6M Horizon
AQST +3.47 pp
1Y Horizon
AQST +6.2 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NUVB Revenue | AQST Revenue | NUVB Op. Margin | AQST Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $70M | N/A | -72.6% | AQST |
| FY2019 | N/A | $50M | N/A | -100.1% | AQST |
| FY2020 | N/A | $50M | N/A | -93.6% | AQST |
| FY2021 | N/A | $50M | N/A | -68.2% | AQST |
| FY2022 | N/A | $50M | N/A | -88.2% | AQST |
| FY2023 | N/A | $50M | N/A | -29.9% | AQST |
| FY2024 | $10M | $60M | -7527.3% | -53.5% | AQST |
| FY2025 | $60M | $40M | -338.7% | -159.5% | AQST |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
NUVB
BREAKDOWN
Current IV
65.2%
IV Percentile
26th %ile
Put/Call OI Skew
0.24x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
AQST
BREAKDOWN
Current IV
87.9%
IV Percentile
64th %ile
Put/Call OI Skew
0.98x (Balanced)
IV Regime
Elevated (60th–80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
NUVB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
AQST Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ NUVB vs AQST Key Questions & Quantitative Answers
As of Nov 20, 2026, Aquestive Therapeutics, Inc. (AQST) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (62.9/100 BUY vs. 61.0/100 BUY) after splitting the core matrix 3–5 (led by Balance Sheet & Cash Flow, Options & Positioning), while NUVB wins 3–2 across the 6-pillar growth and valuation breakdown. NUVB trades at $3.80 (N/M Forward P/E, -61.2% operating margin) versus AQST at $3.46 (N/M Forward P/E, -114.1% operating margin). Growth vs. Quality Trade-Off: AQST earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. NUVB 61.0/100 BUY) and 0.89β · 56% Vol risk profile, whereas NUVB leads top-line expansion (+242.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NUVB leads the Growth & Scale pillar: NUVB posts +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin), compared with AQST at -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NUVB cumulative revenue shifted +500.0% while AQST shifted -42.9%. In operating R&D and SG&A reinvestment, NUVB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AQST.
NUVB screens cheaper on headline valuation multiples. NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin), whereas AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NUVB (-49.1% ROE) versus AQST (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk). By comparison, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
AQST vs NUVB · Reverse Pair
NUVB vs LYEL
· Sector Peer
NUVB vs TSHA
· Sector Peer
NUVB vs STOK
· Sector Peer
AQST vs SVRA
· Sector Peer
AQST vs ETON
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem